The correct version of Table 2 , with the corrected sections indicated in bold:
Originally Table 4 was published as: The correct version of Table 4 , with the corrected sections indicated in bold:
Originally Table 5 was published as: The correct version of Table 5 , with the corrected sections indicated in bold:
Originally the last paragraph of the 'Safety assessment' section was published as:
-Altogether, DA-α had a similar safety profile to that of EPO and no antibody formation was identified.
The correct presentation of the last paragraph of the 'Safety assessment' section, with the corrected words indicated in bold:
-Altogether, DA-α had a similar safety profile to that of EPO and no anti-drug antibody formation was identified.
Originally two sentences in the first paragraph of the 'Discussion' section were published as:
-Evaluating the iron availability for erythropoeisis is crucial in treating anaemia patients with CKD.Iron deficiency can interfere with the response to EPO and DA-α and affecting the efficacy
The correct presentation of two sentences in the first paragraph of the 'Discussion' section, with the corrected words indicated in bold:
-Evaluating the iron availability for erythropoeisis is crucial in treating anaemia patients with CKD. Iron deficiency can interfere with the response to EPO and DA-α and affecting the efficacy 
